Icosavax Provides Corporate Update and Anticipated Milestones for 2022

3 years ago

SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)…

SomaLogic Announces Analyst and Investor Meeting on February 4, 2022

3 years ago

BOULDER, Colo., Jan. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a…

Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

3 years ago

WARREN, N.J., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and…

Rani Therapeutics Appoints Lisa Rometty to Board of Directors

3 years ago

SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a…

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 years ago

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving…

Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million

3 years ago

Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten…

Monopar to Present at the H.C. Wainwright BioConnect Conference

3 years ago

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing…

ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment

3 years ago

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology…

Plus Therapeutics to Participate in Upcoming January Conferences

3 years ago

AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,…

Atea Pharmaceuticals Highlights Strategic Priorities for 2022

3 years ago

COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck…